NCT05356897 2024-09-19
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT04896320 2023-06-22
2019-101826
Providence Health & Services
Phase 1/2 Withdrawn
NCT05227131 2022-07-11
MARGARET
MedSIR
Phase 2 Withdrawn
NCT04512261 2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2 Withdrawn
NCT03846583 2020-10-23
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Dana-Farber Cancer Institute
Phase 1 Withdrawn